KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study.Clin Infect DisPMID 36358012无 PMCID2023-Apr-030.98未发现恶性肿瘤人群证据。待处理
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.Clin Infect DisPMID 36411267PMC100698552023-Apr-030.98未发现恶性肿瘤人群证据。待处理
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.JAMA Netw OpenPMID 37022687PMC100803772023-Apr-030.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical Trials.JAMA Netw OpenPMID 37083668PMC101221742023-Apr-030.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.JAMA Netw OpenPMID 37099299PMC105368802023-Apr-030.98未发现恶性肿瘤人群证据。待处理
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.PainPMID 36066965PMC100268292023-Apr-010.98未发现恶性肿瘤人群证据。待处理
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.J Clin OncolPMID 36455187无 PMCID2023-Apr-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.J Clin OncolPMID 36525610PMC100822492023-Apr-011.00命中用户提供的消化道肿瘤阳性参考集。待处理
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.Ann SurgPMID 36538627PMC99948472023-Apr-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.Int J Radiat Oncol Biol PhysPMID 36566906PMC104623872023-Apr-010.45The study is a Phase 3 randomized trial in oncology (prostate cancer) with a drug-related intervention (PDE5 inhibitors), but the primary efficacy endpoint is erectile function preservation, not a time-to-event endpoint like OS, PFS, or DFS. The reported secondary endpoint 'freedom from biochemical failure' is a time-to-event outcome, but it is not designated as the primary or key secondary endpoint in the abstract, and the trial's main focus is on functional preservation.待处理
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.J Clin OncolPMID 36608310PMC100822992023-Apr-010.98未发现恶性肿瘤人群证据。待处理
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.J Clin OncolPMID 36720083PMC100822852023-Apr-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA OncolPMID 36757706PMC99121652023-Apr-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 36868261无 PMCID2023-Apr-010.98未发现恶性肿瘤人群证据。待处理
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.Obstet GynecolPMID 36897180PMC100269462023-Apr-010.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.LancetPMID 36924778无 PMCID2023-Apr-010.98未发现恶性肿瘤人群证据。待处理
Home Aerobic Training for Cerebellar Degenerative Diseases: a Randomized Controlled Trial.CerebellumPMID 35303255PMC89320902023-Apr0.98未发现恶性肿瘤人群证据。待处理
Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.J Cancer Res Clin OncolPMID 35482076PMC117965842023-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis.Eye (Lond)PMID 35523860PMC101019712023-Apr0.98未发现恶性肿瘤人群证据。待处理
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.Eur UrolPMID 35654659无 PMCID2023-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial.Cannabis Cannabinoid ResPMID 35749710无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.BJU IntPMID 36087070无 PMCID2023-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.Dig Liver DisPMID 36115817无 PMCID2023-Apr0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).EsophagusPMID 36401133PMC100246602023-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.Am J OphthalmolPMID 36410471无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study.J Nucl MedPMID 36418170PMC100717802023-Apr0.90The study is a Phase III randomized trial in oncology (prostate cancer) with original results, but it compares two imaging radiopharmaceuticals for diagnostic accuracy, not a therapeutic drug intervention, and its primary endpoint is a detection rate (a binary outcome), not a time-to-event outcome like OS, PFS, etc. Therefore, it does not meet the required criteria for drug intervention or time-to-event endpoint.待处理
Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers.Phytother ResPMID 36419388无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.J Pediatr UrolPMID 36504158无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.Transplant Cell TherPMID 36526260PMC101898882023-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma.J Allergy Clin Immunol PractPMID 36535524无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Maintenance therapy in multiple myeloma: Two is not always better than one.Br J HaematolPMID 36541138无 PMCID2023-Apr0.80The record is a commentary on the original phase III trial (Jenner et al.). It does not contain the primary formal results with explicit time-to-event endpoint data (e.g., OS, PFS, Kaplan-Meier, HR). Therefore, it is not eligible as an original result report for KM digitization. The 'is_eligible' criterion is set to null because the metadata cannot establish the presence of the required time-to-event endpoint in this specific document.待处理
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.Br J HaematolPMID 36541152PMC109527262023-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial.Clin Transl SciPMID 36564964PMC100870732023-Apr0.98未发现恶性肿瘤人群证据。待处理
Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.Eur J NeurolPMID 36583633无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).J NeurolPMID 36598575PMC100251992023-Apr0.98未发现恶性肿瘤人群证据。待处理
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case Study.Clin Pharmacol TherPMID 36606735无 PMCID2023-Apr0.85The record is a methodological study that emulates a previously completed Phase III trial (CheckMate-057). It is not an original report of a drug's efficacy from a randomized trial. While it references a trial with drug intervention and time-to-event endpoints, this publication itself does not present primary or secondary results for a drug intervention in a trial. It is excluded as a non-original result report and protocol/methodology-focused study.待处理
A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.Clin Pharmacol Drug DevPMID 36648126无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Long-Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial.J Bone Miner ResPMID 36661855无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation.J HepatolPMID 36681160无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer.Clin Genitourin CancerPMID 36697317无 PMCID2023-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
First bovine vaccine to prevent human schistosomiasis - a cluster randomised Phase 3 clinical trial.Int J Infect DisPMID 36736992无 PMCID2023-Apr0.98未发现恶性肿瘤人群证据。待处理
Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy.Clin Oncol (R Coll Radiol)PMID 36737311无 PMCID2023-Apr0.85The study is an eligible Phase III randomized oncology trial with time-to-event endpoints, but it compares two non-drug interventions (brachytherapy vs. radical prostatectomy). As no drug-containing intervention is present, it does not meet the full eligibility criteria for this cohort.待处理
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab-chemotherapy responsive elderly DLBCL patients: A LYSA group study.Br J HaematolPMID 36740991无 PMCID2023-Apr0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.Adv TherPMID 36749544PMC100702242023-Apr0.98未发现恶性肿瘤人群证据。待处理
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.Br J CancerPMID 36759720PMC100704172023-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effects of preoperative magnetic resonance image on survival rates and surgical planning in breast cancer conservative surgery: randomized controlled trial (BREAST-MRI trial).Breast Cancer Res TreatPMID 36786946PMC100364392023-Apr0.95The trial is a Phase III randomized controlled trial in human breast cancer with time-to-event endpoints (LRFS, OS). However, it does not meet the 'drug-containing intervention' requirement as the intervention is preoperative MRI, not a drug. Therefore, it is ineligible.待处理
Macroscopic and multiple metastases in sentinel lymph node biopsy are respectively associated with poor prognosis in early oral cancer.Int J Clin OncolPMID 36795281无 PMCID2023-Apr0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.Lancet Gastroenterol HepatolPMID 36801007无 PMCID2023-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.Dig Liver DisPMID 36804053无 PMCID2023-Apr0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.Lung CancerPMID 36806898无 PMCID2023-Apr0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理